Skip to main content
Premium Trial:

Request an Annual Quote

Decode Logs 13-Percent Drop in Q4 Revenues Amid Swelling R&D Costs and Loss

NEW YORK, March 7 (GenomeWeb News) - Decode Genetics yesterday reported an approximately 13-percent decrease in revenues amid escalating losses for the fourth quarter.

 

Decode's revenues for the three months ended Dec.31, 2005, dropped to $9.8 million from $11.2 million year over year.

 

Research and development expenses increased nearly 60 percent to $13.7 million for the fourth quarter from $8.7 million for the same period in 2004, Decode said, primarily to support its drug-development programs.

 

The company's net loss grew to $21.1 million from $19.4 million in the year-ago period. Decode attributed the spike in net loss to the increased R&D expenses.

 

Decode had $155.6 million in cash and investments on hand asof Dec. 31.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.